Show simple item record

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.

dc.contributor.authorDavidson, M
dc.contributor.authorStarling, N
dc.date.accessioned2016-12-19T14:46:10Z
dc.date.issued2016-01
dc.identifier.citationOncoTargets and therapy, 2016, 9 pp. 7235 - 7245
dc.identifier.issn1178-6930
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/337
dc.identifier.eissn1178-6930
dc.identifier.doi10.2147/ott.s100643
dc.description.abstractThe addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.
dc.formatElectronic-eCollection
dc.format.extent7235 - 7245
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.
dc.typeJournal Article
rioxxterms.versionofrecord10.2147/ott.s100643
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2016-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncoTargets and therapy
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNo embargo
icr.researchteamGastrointestinal Cancers Clinical Trialsen_US
dc.contributor.icrauthorStarling, Naureen


Files in this item

Thumbnail
Name:
Starling 2016.pdf
Size:
1.643Mb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0